More on ABBV
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $215.40 |
|
|||
| Open | $214.80 | ||||
| 52 Wk High | $68.12 | ||||
| 52 Wk Low | $50.71 | ||||
| Day High | $219.54 | ||||
| Day Low | $213.73 | ||||
| P/E | 47.10 | ||||
| EPS | $4.61 | ||||
| Volume | 5,665,406 | ||||
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Form SD AbbVie Inc.
- AbbVie gets EU approval for expanded VENCLYXTO cancer drug combinations
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA approves AbbVie's DECNUPAZ for rare blood cancer treatment
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatme
- FDA approves AbbVie's pivekimab sunirine-PVZY for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy
- Form 144 AbbVie Inc. Filed by: Alpern Robert J
- AbbVie receives positive EU committee opinion for hepatitis C drug
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
Entities mentioned with ABBV
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Dividend | View Related Stories »
- Show More...
